Introduction Severe immune‐related adverse events (irAEs) due to immune checkpoint
inhibitors (ICIs) can lead to admission to the intensive care unit (ICU). In this retrospective …

Background Immune checkpoint inhibitors have reshaped the standard of care in oncology.
However, they have been associated with potentially life-threatening immune-related …

Background Immune checkpoint inhibitors (ICI) have revolutionized the management of
cancer. They can induce immune-related adverse events (irAE) leading to intensive care …

Aim Hospital admissions secondary to immune‐related adverse events (irAE) arising from
immune checkpoint inhibitors (ICI) are likely to increase with increasing use of this class of …

Background As immune checkpoint inhibitors (CPI) are increasingly approved for cancer
treatment, hospitalizations related to severe immune-related adverse events (irAE) will …

3096 Background: Disruption of the immune system using immune checkpoint inhibitors can
result in a multitude of immune-related adverse effects (irAE). While irAEs have been well …

127 Background: Disruption of the immune system with immune checkpoint inhibitors can
result in a multitude of immune-related adverse effects (irAE). While irAEs have been well …

Introduction Immune checkpoint inhibitors (ICIs) have become the standard of care in many
cancer types. As the number of patients receiving ICIs for various cancers continues to …

Background Due to the use of checkpoint inhibitors, intensive care units will be confronted
with an increasing number of patients with immune-related adverse events. A broad …

Objective To determine the proportion of emergency patients treated with immune
checkpoint inhibitors (ICIs) that require critical care admission and their requirements …